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RESISTANCES AND VIRULENCE FORMS FOR 
Klebsiella pneumoniae IN HOSPITAL 
ENVIRONMENTS 
INTRODUCTION 
 Klebsiella pneumoniae is a saprophytic bacteria that lives in a gastrointestinal tract, skin and 
nasopharynx of humans.  
 It’s the causing of infections of urinary tract and biliary tract, osteomyelitis and bacteriemia. 
This pathogen acts using different virulence factors. 
 The formation of biofilms is a big problem to consider in hospital environment.  
 This capacity is due to the proteins MrkA and MrkD. 1 Different studies have demonstrated 
that biofilms of K. pneumoniae are resistant to ciprofloxacin, tetracycline and chloramphenicol.   
 Extended spectrum beta-lactamase (ESBL): 
Extended spectrum beta-lactamases are enzymes with the ability to 
hydrolyze different types of drugs. High amount of these enzymes are 
included in chromosome and probably are related with penicillin-
binding proteins. 2 
 
 
 
 
 
 
 
 
 Carbapenemase-producing  
K. pneumoniae (KPC): 
Many of the carbapenemases are present 
in chromosomes, but the most of them are 
encoded on mobile genetic elements, what 
allows their dissemination. For example, 
the transposon Tn4401 (found on 
plasmids) contains the gene blaKPC, the 
KPC-encoding gene.3 
 
 
 
 
 
 
 
 
 AmpC beta-lactamase: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Metallo-beta-lactamase (MBL): 
As the rest of beta–lactamases, MBLs can 
be encoded in mobile genetic elements 
and plasmids or normally chromosomally 
encoded. However, in the past 3 to 4 
years many new transferable types of 
MBLs have been studied and it’s thought 
that they are spreading fast.5 
 
 
 
 
 
 
 
 
 
 
 
 
ACTUAL VISION 
 
 
 
 
 
 
 
 
 
 
 
DRUG ANTIBIOTIC CLASS SPECTRUM 
Ceftaroline Cephalosporin AmpC beta-lactamaseproducers 
Ceftazidime/avibactam Beta-lactam+beta-lactamase inhibitor ESBLs, KPC, ampC beta-lactamase producers 
Ceftobiprole Cephalosporin AmpC beta-lactamases  producers 
Delafloxacin Quinolone MDR (multi-drug resistant) Gram-negative 
Doripenem Carbapenem ESBLs, MBLs, ampC beta-lactamase producers 
Eravacycline Tetracycline ESBLs and KPCs producers 
Finafloxacin Quinolone MDR Gram-negative 
MK-7655 Beta-lactamase inhibitor KPC producers 
Omadacycline Tetracycline ESBLs and KPCs producers 
Panipenem Carbapenem ESBLs, MBLs, ampC beta-lactamase producers 
Plazomicin Aminoglycoside MDR gram-negative including metallo-beta-lactamase 
Razupenem Carbapenem ESBLs and KPCs producers  
Tebipenem Carbapenem ESBLs producers 
Tomopenem Carbapenem ESBLs and ampC beta-lactamase producers 
Resistance to: 
Penicillins 
Aztreonam 
Cephalosporins 
(except cefepime) 
Monobactams 
Inhibited by: 
clavulanic acid, 
sulbactam, 
tazobactam and 
carbapenems. 
Resistance to: 
Penicillins, 
Cephalosporins 
Monobactams 
Imipenem 
Meropenem 
 
Temociline   
Amdinocillin 
Clavulanic acid 
Sulbactam  
Tazobactam  
Inhibited by: 
fluoroquinolones, 
tigecycline and in 
occasions 
tazobactam and 
sulbactam. 
Beta-lactams, Aminoglicosids, 
Kanamycine,, Amikacin, Streptomycin. 
Inhibited by: polymyxin, but the 
combinations as aztreonam, meropenem 
and colistin are too.  
CONCLUSIONS 
The emergency of multiresistent strain of K. pneumoniae is increasing constantly, so we need to create more novel antibiotics, combine different 
types of antibiotics to provide at patients and have under control the infections for these microorganisms.  
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Fig.1: K. pneumoniae in vitro biofilm obtained 
by Confocal Laser Scanning Microscopy (CLSM). 
Fig. 2: Virulence factors of K. pneumoniae.  
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Table 1: Activity of new antibiotics against ESBLs, KPCs and MBLs pathogens. 
 New molecules are in development to face resistant K. 
pneumoniae, especially carbapenemase producers.  
 The antibiotics that are the most important and 
potentially active against K. pneumoniae are new 
carbapenems, the combination of avibactam with 
ceftazidime, and plazomicin among others. 
 Due to the promising antibiotics are in this moment in 
development, we need to approve these new molecules 
during the next years considering that are an important 
point for the future. 6 
Fig. 3: Proves of resistance in double-
disc synergism for detect ESBLs.  
Resistance to: 
Imipenem 
Meropenem 
Cephalosporins
Gentamicin  
Tigecycline 
Fosfomicine 
Colistin 
Polymyxin B 
A mutation on genes ampA and 
ampB has resulted in an 
increased resistance. The ampC 
gene has been suggested as the 
structural gen for the beta-
lactamase, after the 
observation of that a mutation 
in this gen led to the down-
expression of this enzyme on 
the mutant strains.4 
